Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
The company expects meaningful revenue contribution from this long-term agreement
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
